
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Xetra | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZNPy | TradeGate | EUR | Delayed | |
AZNm | Buenos Aires | ARS | Delayed | |
A1ZN34 | B3 | BRL | Delayed | |
AZNA | Vienna | EUR | Real-time |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Pascal Soriot | 62 | 2012 | CEO & Executive Director |
Michel Demare | 68 | 2019 | Independent Chairman |
Jeffrey Pott | - | 2009 | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
Pam P. Cheng | 52 | 2015 | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
Aradhana Sarin | 48 | 2021 | CFO & Executive Director |
Marcus Wallenberg | 68 | 1999 | Non-Executive Director |
Sherilyn S. D. McCoy | 65 | 2017 | Independent Non-Executive Director |
Philip Arthur John Broadley | 63 | 2017 | Senior Independent Non-Executive Director |
Nazneen Rahman | 55 | 2017 | Independent Non-Executive Director |
Shu Kam Mok | 65 | 2019 | Independent Non-Executive Director |
Euan Angus Ashley | 54 | 2020 | Independent Non-Executive Director |
Rain Henderson | - | - | Member of External Sustainability Advisory Board |
Anna Olive Magdelene Manz | 52 | 2023 | Non-Executive Director |
Karen E. Knudsen | - | 2025 | Director |
Louise Nicholls | - | - | Member of External Sustainability Advisory Board |
Polly Courtice | 73 | - | Member of External Sustainability Advisory Board |
Diana Louise Patricia Layfield | 55 | 2020 | Independent Non-Executive Director |
Pankaj Bhatia | - | - | Member of External Sustainability Advisory Board |
Birgit M. Conix | 60 | 2025 | Non-Executive Director |
Rene Anthony Andrada Haas | 63 | 2025 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review